Livagen (Livagen (Lys-Glu-Asp-Ala Liver/Lymphocyte Bioregulator))
A short synthetic peptide bioregulator from the Khavinson family (an analog related to Vilon) associated with liver tissue and lymphocyte function. Used in the bioregulator community for liver support and chromatin/gene-expression effects.
How it works
As a signal peptide (Lys-Glu-Asp-Ala), it is proposed to decondense chromatin (heterochromatin) in lymphocytes and regulate gene expression in hepatic tissue, supporting liver function and cellular activity.
Key facts
- Molecular weight: ~460 Da
- Half-life: Short (peptide)
- Bioavailability: Oral (encapsulated) or subcutaneous
- Storage: Room temperature (capsules) or refrigerate (injectable).
Dosing overview
- Typical dose: ~1-2 capsules/day or short injectable courses
- Frequency: Once daily
- Duration: 10-30 day courses
- Route: Oral capsule or subcutaneous
Protocol notes
- Taken as short repeatable courses (often 10-30 days), a few times per year.
- Oral encapsulated forms are taken once daily on an empty stomach.
- Often used with other detox and liver-support compounds.
Reported benefits
- Liver function support
- Lymphocyte chromatin activation (proposed)
- Detox/antioxidant support
- Short course-based protocol
Possible side effects
- Limited Western clinical data
- Injection site reactions (injectable)
- Unknown long-term effects
Research
- Livagen chromatin decondensation (2003): Reported to decondense heterochromatin and activate gene expression in human lymphocytes in cell studies.
Compare Livagen
Research and educational reference only. Not medical advice.